Phenyl Compounds Inhibiting Amyloid Beta for Alzheimer's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease primarily manage symptoms but lack a cure, and there is an unmet need for effective therapeutics that can address the underlying mechanisms driving the progression of the disease, such as amyloid β accumulation.
Innovation Solution
Development of phenyl compounds that inhibit the production of amyloid β and tau proteins, which are administered to subjects to attenuate their levels and associated signaling pathways, thereby potentially slowing disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current AD medications are used to manage symptoms, then symptom relief is achieved, but the underlying disease progression driven by amyloid β accumulation is not addressed
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism of amyloid β accumulation and tau protein production by designing compounds that selectively inhibit beta-secretase and gamma-secretase enzymes. This extraction of the core pathological process allows for targeted intervention rather than general symptom management, directly addressing the underlying disease progression while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent employs parameter changes by modifying molecular structures of compounds to optimize their inhibitory activity against amyloidogenic enzymes. By systematically varying chemical parameters such as substituent groups on the phenyl ring and adjusting molecular properties, the invention achieves compounds with enhanced specificity and potency against the disease mechanism while maintaining drug-like characteristics for effective therapy.
2Reliability
If phenyl compounds are developed to inhibit amyloid β production, then underlying disease mechanisms are addressed, but the complexity of drug development increases
Solution Approach 1:
The patent segments the complex drug development process into manageable components by focusing on specific enzymatic targets (beta-secretase and gamma-secretase) and designing compounds with modular structures. The phenyl compound framework is divided into identifiable substituent positions that can be independently optimized, allowing systematic development of inhibitors that target disease mechanisms without requiring overly complex molecular structures.
Solution Approach 2:
The patent achieves universality by designing a phenyl compound scaffold that can serve multiple therapeutic functions: inhibiting amyloid β production, modulating tau protein levels, and potentially addressing other aspects of Alzheimer's pathology. This multi-functional approach allows a single compound class to target multiple disease mechanisms, reducing the need for separate complex interventions for each pathological feature.
Data Source
AI summary
Provided herein are compounds, for example, a compound of Formula (I), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disorder, disease, or condition.